2014
DOI: 10.1002/hep.27369
|View full text |Cite
|
Sign up to set email alerts
|

Circulating MicroRNAs as a marker for liver injury in human immunodeficiency virus patients

Abstract: Human immunodeficiency virus (HIV) and hepatitis virus coinfection amplify and accelerate hepatic injury. MicroRNAs (miRNAs) are small regulatory RNAs suggested as biomarkers for liver injury. We analyzed the circulating levels of miRNAs in HIV patients with regard to the extent and etiology of liver injury. Total RNA was extracted from 335 serum samples of HIV patients and 22 healthy control participants using Qiazol. Comprehensive polymerase chain reaction (PCR) array analyses (768 miRNA) were performed in s… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
44
0

Year Published

2015
2015
2019
2019

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 57 publications
(44 citation statements)
references
References 47 publications
0
44
0
Order By: Relevance
“…For example, intracellular levels of miRNAs and/or levels of secretion may fluctuate at different stages of rejection, which may complicate interpretation of the data. For example, circulating liver-specific miRNA-122 is dramatically up-regulated during liver injury [69,70,71,72,73], but significantly down-regulated during late-stage hepatic cirrhosis [75] and hepatocellular carcinoma [76,77], due to intracellular down-regulation of miRNA production. Therefore, levels of certain circulating organ-specific miRNAs may be significantly up-regulated during acute rejection, but significantly down-regulated during chronic or late rejection.…”
Section: Discussion—challenges and Solutionsmentioning
confidence: 99%
See 2 more Smart Citations
“…For example, intracellular levels of miRNAs and/or levels of secretion may fluctuate at different stages of rejection, which may complicate interpretation of the data. For example, circulating liver-specific miRNA-122 is dramatically up-regulated during liver injury [69,70,71,72,73], but significantly down-regulated during late-stage hepatic cirrhosis [75] and hepatocellular carcinoma [76,77], due to intracellular down-regulation of miRNA production. Therefore, levels of certain circulating organ-specific miRNAs may be significantly up-regulated during acute rejection, but significantly down-regulated during chronic or late rejection.…”
Section: Discussion—challenges and Solutionsmentioning
confidence: 99%
“…In recent years, a large number of reports have been published indicating that circulating miR-122 can be applied as a non-invasive biomarker for a wide spectrum of clinical liver-specific diseases, including hepatic virus infections [61,62,63,64,65,66,67,68], liver injury [69,70,71,72,73], hepatic cirrhosis [74,75], and hepatocellular carcinoma [65,76,77] (reviewed in [60]). By reviewing the published papers, we have summarized the information, and it suggests that circulating miR-122 is the most frequent biomarker for liver disease (Figure 2).…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…RNA was isolated from samples using the Qiazol reagent as instructed by the manufacturer (Qiagen, Hilden, Germany) (Trebicka et al, 2013;Anadol et al, 2015). The following assays provided by Applied Biosystems (Foster City, USA) were used: ACTA2 (αSMA, Hs00426835_g1), COL1A1 (Hs00164004_m1), Src (Rn01418228_m1) PDGFRB (Hs01019589_m1), RHOA (for human; Hs01051295-m1), and RhoA (for rat; Rn04219609_m1).…”
Section: Qrt-pcrmentioning
confidence: 99%
“…As for example, circulating liver-specific miRNA-122 was found to be up-regulated on liver injury [28,32,33]; whereas, significantly down-regulated during late-stage hepatic cirrhosis [34] and hepatocellular carcinoma [35] due to intracellular down-regulation of miRNA production. Therefore, levels of certain circulating miRNAs may be significantly up-regulated during acute phases, or down-regulated thereafter.…”
mentioning
confidence: 99%